Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
NCT ID: NCT04079374
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
160 participants
INTERVENTIONAL
2018-09-03
2023-12-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To compare the efficacy and safety of Etanercept, lyophilisate for solution for injection and Enbrel, lyophilisate for solution for subcutaneous injection, which are used as subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks in combination with methotrexate in patients with rheumatoid arthritis.
2. To prove the therapeutic equivalence of Etanercept, lyophilisate for solution for injection and Enbrel, lyophilisate for solution for subcutaneous injection in patients with rheumatoid arthritis.
3. To evaluate the immunogenicity of Etanercept, lyophilisate for solution for injection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
NCT00706797
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
NCT02373813
Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy
NCT00244556
Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis
NCT03332719
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry
NCT01646385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Total duration of patient participation in the study will be 49-52 weeks. Of these: screening - up to 4 weeks, treatment - 24 weeks, follow-up after treatment - 4 weeks, evaluation of the study drug immunogenicity - 52 weeks after the treatment initiation.
Patients receive Etanercept or Enbrel (depending on the group) in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept
Patients receive Etanercept in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
Etanercept
Subcutaneous injections
Enbrel
Patients receive Enbrel in the form of subcutaneous injections at a dose of 25 mg 2 times a week for 24 weeks.
Enbrel
Subcutaneous injections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etanercept
Subcutaneous injections
Enbrel
Subcutaneous injections
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* body weight \> 45 kg;
* patients diagnosed with: rheumatoid arthritis (RA) of moderate and high activity, according to the classification of RA criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) of 2010;
* functional class I, II or III according to the Classification of the Functional Class of the RA of the American College of Rheumatology (ACR);
* number of painful joints (NPJ) ≥ 6 (68 joints examined), number of swollen joints (NSJ) ≥6 (66 joints examined);
* ESR (Erythrocyte sedimentation rate)≥ 28 mm/hour or СRP (C - reactive protein) \> 7.0 mg/dl;
* patient who receive methotrexate for at least 12 weeks at doses of 7.5-20 mg/week (orally or parenterally), and the dose and route of administration of methotrexate was not changed for 4 weeks before randomization;
* patient who stopped therapy with other basic antirheumatic drugs, except methotrexate, and completed the wash-out period for these drugs of at least five half-life periods, but not less than 2 weeks (whichever is longer);
* if a patient takes NSAIDs (Nonsteroidal anti-inflammatory drugs), the dose of the drug should be stable within 2 weeks before randomization;
* if a patient takes oral glucocorticosteroids, the dose should be ≤10 mg/day of prednisolone (or equivalent) and be stable for 2 weeks before randomization;
* women of childbearing age and men who have partners, who have agreed to use reliable contraceptive methods during the entire study period and within 3 months after its termination. Reliable methods of contraception include: intrauterine devices, double-barrier method or state after surgical sterilization and vasectomy;
* signed informed consent of participants to participate in this study, which was obtained before any screening procedures, including discontinuation of forbidden-drugs.
Exclusion Criteria
* other rheumatic diseases, autoimmune diseases, connective tissue diseases, immunodeficiency (e.g. psoriasis, psoriatic arthritis, primary Sjogren syndrome, systemic lupus erythematosus or demyelinating diseases such as multiple sclerosis);
* septic arthritis within 12 months before screening; purulent arthritis of prosthetic joints;
* acute or frequent recurrent chronic, local or generalized infections (bacterial/fungal/viral) or sepsis, or history of recurrent infections, or increased risk of developing infections or sepsis;
* an active form of tuberculosis; the history of the ineffective treatment of tuberculosis; latent tuberculosis or risk of developing tuberculosis (e.g., contact with patients who have an active form of tuberculosis, shortly before screening);
* severe interstitial lung diseases (bronchial asthma, chronic obstructive pulmonary disease, bronchiectasis, fibrosis);
* malignant diseases, including history (except successfully treated non-metastatic basal cell or squamous cell skin cancer or cervical cancer);
* congestive heart failure of class III or IV, according to New York Heart Association criteria, or unstable angina;
* uncontrolled diabetes mellitus, uncontrolled arterial hypertension;
* abnormal laboratory parameters at screening:
* haemoglobin \< 100.0 g/L;
* platelets \< 125 \*10\^9 cell/L;
* leukocytes \< 3.5 \*10\^9 cell/L,
* absolute neutrophil count \< 1.5 \*10\^9 cell/L;
* absolute lymphocyte count \< 0.8 \*10\^9 cell/L;
* ASТ (Aspartate aminotransferase), АLТ (Alanine aminotransferase) 3 and more times higher than the upper limit of normal and serum total bilirubin 2 and more times higher than the upper limit of normal;
* serum creatinine 2 times or higher than the upper limit of normal;
* history of clinically significant or uncontrolled diseases of the respiratory system, liver, kidney, blood, gastrointestinal tract, endocrine system, immune system, skin, nervous system (including demyelinating disorders), cardiovascular system, or history of an autoimmune or mental disorder, or any condition which, in the opinion of the Investigator, can pose a threat to the safety of a patient, affect the study results or prevent a patient from completing the study;
* hepatitis В, С;
* scheduled surgical intervention including joint replacement during the study;
* recent chickenpox;
* oral and gastrointestinal ulcers;
* pregnancy, breastfeeding;
* history of alcohol or drug abuse;
* vaccination with live or attenuated vaccines within 4 weeks before the screening, or scheduled vaccination during the study, or within 3 months after the last dose of the study/reference drug;
* previous treatment with any other GEBD (genetically engineered biological drugs) (GEBD) for rheumatoid arthritis (including, tocilizumab, adalimumab, anakinra, abatacept, infliximab, rituximab, golimumab, Etanercept, certolizumab) or tofacitinib;
* use of systemic or intraarticular corticosteroids, except prednisolone at a dose of≤10 mg/day orally, or equivalent to GCS (Glucocorticosteroids) within 2 weeks before randomization;
* use of alkylating agents (e.g. cyclophosphamide, chlorambucil) within 6 months before randomization;
* use of intravenous or oral antimicrobial agents 4 weeks before randomization; simultaneous participation in any other clinical study, or participation in a clinical study within 3 months before screening.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
INDUSTRY
Joint Stock Company "Farmak"
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mykola Stanislavchuk, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Vinnitsa Regional Clinical Hospital Named after N.I.Pirogov
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PU Kryvyi Rih City Clinical Hospital №2 of the Dnipropetrovsk regional council
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
PU Kryvyi Rih City Clinical Hospital №8 of the Dnipropetrovsk regional council
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
Ivano-Frankivsk Central City Clinical Hospital
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Communal non-commercial enterprise of Kharkiv Regional Council Regional Hospital of the war veterans
Kharkiv, Kharkivs’ka Oblast’, Ukraine
Municipal nonprofit enterprise City Multidisciplinary Hospital № 18 of Kharkiv City Council
Kharkiv, Kharkivs’ka Oblast’, Ukraine
Khmelnytskyi Regional Hospital
Khmelnytskyi, Khmelnytskyi Oblast, Ukraine
Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital
Lviv, Lviv Oblast, Ukraine
Ternopil University Hospital
Ternopil, Ternopil Oblast, Ukraine
Vinnitsa Regional Clinical Hospital Named After N.I.Pirogov
Vinnitsa, Vinnitsa Region, Ukraine
Municipal Institution O.Herbachevskiy Regional State Clinical Hospital
Zhytomyr, Zhytomyr Oblast, Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Natalyia Kolb
Role: backup
Zoryana Mysliborska
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FM-ENRT-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.